Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy

被引:38
|
作者
Kim, Hyo Song [1 ,6 ]
Lee, Jeeyun [1 ]
Yi, Seong Yoon [1 ]
Jun, Hyun Jung [1 ]
Choi, Yoon-La [2 ]
Ahn, Geung Hwan [2 ]
Seo, Sung Wook [3 ]
Lim, Do Hoon [4 ]
Ahn, Yong Chan [4 ]
Park, Joon Oh [1 ]
Kim, Sung Joo [5 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthoped Surg, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea
[6] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
来源
BMC CANCER | 2009年 / 9卷
关键词
SOFT-TISSUE SARCOMAS; RADIATION-THERAPY; RANDOMIZED TRIAL; EXTREMITY; CLASSIFICATION; MANAGEMENT; RECURRENCE; SURVIVAL; SUBTYPE; TRUNK;
D O I
10.1186/1471-2407-9-205
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Prognosis and optimal treatment strategies of liposarcoma have not been fully defined. The purpose of this study is to define the distinctive clinical features of liposarcomas by assessing prognostic factors. Methods: Between January 1995 and May 2008, 94 liposarcoma patients who underwent surgical resection with curative intent were reviewed. Results: Fifty patients (53.2%) presented with well differentiated, 22 (23.4%) myxoid, 15 (16.0%) dedifferentiated, 5 (5.3%) round cell, and 2 (2.1%) pleomorphic histology. With the median 14 cm sized of tumor burden, about half of the cases were located in the retroperitoneum (46.8%). Seventy two (76.6%) patients remained alive with 78.1%, and 67.5% of the 5- and 10-year overall survival (OS) rates, respectively. Low grade liposarcoma (well differentiated and myxoid) had a significantly prolonged OS and disease free survival (DFS) with adjuvant radiotherapy when compared with those without adjuvant radiotherapy (5-year OS, 100% vs 66.3%, P = 0.03; 1-year DFS, 92.9% vs 50.0%, respectively, P = 0.04). Independent prognostic factors for OS were histologic variant (P = 0.001; HR, 5.1; 95% CI, 2.0 - 12.9), and margin status (P = 0.005; HR, 4.1; 95% CI, 1.6 - 10.5). We identified three different risk groups: group 1 (n = 66), no adverse factors; group 2, one or two adverse factors (n = 28). The 5- year OS rate for group 1, and 2 were 91.9%, 45.5%, respectively. Conclusion: The histologic subtype, and margin status were independently associated with OS, and adjuvant radiotherapy seems to confer survival benefit in low grade tumors. Our prognostic model for primary liposarcoma demonstrated distinct three groups of patients with good prognostic discrimination.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy
    Hyo Song Kim
    Jeeyun Lee
    Seong Yoon Yi
    Hyun Jung Jun
    Yoon-La Choi
    Geung Hwan Ahn
    Sung Wook Seo
    Do Hoon Lim
    Yong Chan Ahn
    Joon Oh Park
    Sung Joo Kim
    BMC Cancer, 9
  • [2] Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy
    Lee, J
    Park, YH
    Kim, WS
    Lee, SS
    Ryoo, BY
    Yang, SH
    Park, KW
    Kang, JH
    Park, JO
    Lee, SH
    Kim, K
    Jung, CW
    Park, YS
    Im, YH
    Kang, WK
    Lee, MH
    Ko, YH
    Ahn, YC
    Park, K
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (10) : 1402 - 1408
  • [3] PROGNOSTIC FACTORS IN LIPOSARCOMA
    REITAN, JB
    KAALHUS, O
    BRENNHOVD, IO
    SAGER, EM
    STENWIG, AE
    TALLE, K
    CANCER, 1985, 55 (10) : 2482 - 2490
  • [4] Improved Stratification of Standard Risk Medulloblastoma Patients by Clinical and Biological Prognostic Factors
    Rutkowski, S.
    von Bueren, A. O.
    Gerber, N. U.
    Clifford, S. C.
    Ellison, D. W.
    Grotzer, M. A.
    Hartmann, W.
    zur Muehlen, A.
    O'Toole, K.
    Nicholson, S.
    Kortmann, R. D.
    Lannering, B.
    Pietsch, T.
    KLINISCHE PADIATRIE, 2009, 221 (03): : 206 - 206
  • [5] Retroperitoneal liposarcoma: the role of adjuvant radiation therapy and the prognostic factors
    Lee, Hong Seok
    Yu, Jeong Il
    Lim, Do Hoon
    Kim, Sung Joo
    RADIATION ONCOLOGY JOURNAL, 2016, 34 (03): : 216 - 222
  • [6] Salvage radiotherapy of prostate cancer: a risk stratification system based on prognostic factors
    Bisello, S.
    Arcelli, A.
    Deodato, F.
    Dominsky, N.
    Tarantino, G.
    Ntreta, M.
    Cilla, S.
    Siepe, G.
    Cavallini, L.
    Pezzulla, D.
    Alitto, A. R.
    Re, A.
    Cammelli, S.
    Cortesi, A.
    Romeo, A.
    Frezza, G. P.
    Morganti, A. G.
    Macchia, G.
    Buwenge, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1142 - S1143
  • [7] Adjuvant radiotherapy of prostate cancer: a risk stratification system based on prognostic factors
    Bisello, S.
    Arcelli, A.
    Deodato, F.
    Dominsky, N.
    Tarantino, G.
    Ntreta, M.
    Cilla, S.
    Siepe, G.
    Cavallini, L.
    Pezzulla, D.
    Alitto, A. R.
    Re, A.
    Cammelli, S.
    Cortesi, A.
    Romeo, A.
    Frezza, G. P.
    Morganti, A. G.
    Macchia, G.
    Buwenge, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1129 - S1130
  • [8] Curative radiotherapy of prostate cancer: a risk stratification system based on prognostic factors
    Bisello, S.
    Arcelli, A.
    Deodato, F.
    Dominsky, N.
    Tarantino, G.
    Ntreta, M.
    Cilla, S.
    Siepe, G.
    Cavallini, L.
    Pezzulla, D.
    Alitto, A. R.
    Cammelli, S.
    Cortesi, A.
    Romeo, A.
    Frezza, G. P.
    Morganti, A. G.
    Macchia, G.
    Buwenge, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1141 - S1142
  • [9] Prognostic factors and risk stratification in early mycosis fungoides
    Vonderheid, Eric C.
    Pavlov, Igor
    Delgado, Julio C.
    Martins, Thomas B.
    Telang, Gladys H.
    Hess, Allan D.
    Kadin, Marshall E.
    LEUKEMIA & LYMPHOMA, 2014, 55 (01) : 44 - 50
  • [10] Prognostic factors and risk stratification in chronic lymphocytic leukemia
    Parikh, Sameer A.
    Shanafelt, Tait D.
    SEMINARS IN ONCOLOGY, 2016, 43 (02) : 233 - 240